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Abstract
Wildlife and humans are increasingly competing for resources worldwide, and a diverse,
innovative, and effective set of management tools is needed. Controlling abundance of wild-
life species that are simultaneously protected, abundant, competitive for resources, and in
conflict with some stakeholders but beloved by others, is a daunting challenge. Free-ranging
horses (Equus caballus) present such a conundrum and managers struggle for effective
tools for regulating their abundance. Controlling reproduction of female horses presents a
potential alternative. During 2009–2017, we determined the long-term effectiveness of
GnRH vaccine (GonaCon-Equine) both as a single immunization and subsequent reimmuni-
zation on reproduction and side effects in free-ranging horses. At a scheduled management
roundup in 2009, we randomly assigned 57 adult mares to either a GonaCon-Equine treat-
ment group (n = 29) or a saline control group (n = 28). In a second roundup in 2013, we
administered a booster vaccination to these same mares. We used annual ground observa-
tions to estimate foaling proportions, social behaviors, body condition, and injection site
reactions. We found this vaccine to be safe for pregnant females and neonates, with no
overt deleterious behavioral side effects during the breeding season. The proportion of
treated mares that foaled following a single vaccination was lower than that for control
mares for the second (P = 0.03) and third (P = 0.08) post-treatment foaling seasons but was
similar (P = 0.67) to untreated mares for the fourth season, demonstrating reversibility of the
primary vaccine treatment. After two vaccinations, however, the proportion of females giving
birth was lower (P <0.001) than that for control mares for three consecutive years and ran-
ged from 0.0–0.16. The only detectable adverse side effect of vaccination was intramuscular
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swelling at the vaccination site. Regardless of vaccine treatment (primary/secondary),
approximately 62% (34/55) of immunized mares revealed a visible reaction at the vaccine
injection site. However, none of these mares displayed any evidence of lameness, altered
gait or abnormal range of movement throughout the 8 years they were observed in this
study. Our research suggests that practical application of this vaccine in feral horses will
require an initial inoculation that may provide only modest suppression of fertility followed by
reimmunization that together could result in greater reduction in population growth rates
over time.
Introduction
Anthropogenic disturbance of landscapes and natural resources is pervasive across much of
the earth, resulting in increased conflict between humans and wildlife and a need for effective
resource management [1]. Humans indeed have tried to control animal abundance in some
capacity for over 13,000 years [2]. Regulating abundance of wild animals using fertility control
or contraception is a relatively new development, emerging only 50 years ago [3]. Such tools
are appealing to wildlife managers and stakeholders because they present a non-lethal solution
for regulating abundance when species pose a risk to human interests and safety, and when
wildlife densities are high enough to disrupt ecosystem function [4,5].
Feral horses (Equus caballus) present perhaps one of the most unique wildlife management
problems worldwide. Humans have spent centuries propagating and dispersing domestic
horses to every continent except Antarctica over the last several centuries, only to have inad-
vertently created expansive feral populations that now compete with humans, wildlife, and
domestic animals for resources [6]. The unique relationship between humans and horses has
resulted in a precarious dichotomy, with the struggle for relief from conflict and resource com-
petition challenged by a mutualistic societal view where feral horses are perceived as part of
our social environment. This struggle is elevated in the United States, where federal law (P. L.
92–195, as amended) provides protection for feral horses and burros (Equus asinus) on large
expanses of public land, and establishes guidance for their management as a wildland species
[7].
Current methods of population control for free-ranging horses in the U.S. involve periodic
removals and adoption or sale of surplus animals, or maintaining excess animals in long-term
holding facilities which are expensive, resource intensive, and unsustainable [8]. Clearly, more
efficient, cost effective, and humane approaches to reducing feral horse densities on public
lands are needed. Controlling the fertility of female horses offers a potential complementary or
alternative strategy for limiting the growth of some populations [9].
A promising immunological approach to contraception in feral horses and other wild
ungulate species involves immunization against gonadotropin- releasing hormone (GnRH), a
small neuropeptide that performs an obligatory role in mammalian reproduction [10]. When
conjugated to a highly immunogenic carrier protein and combined with a potent adjuvant,
GnRH vaccination actively stimulates a persistent immune response resulting in prolonged
antibody production against endogenous GnRH. These antibodies induce transient infertility
by binding to GnRH, thus preventing attachment to receptors on pituitary gonadotropes, sup-
pression of gonadotropin release, and ultimately ovulation in females [11, 12]. As anti-GnRH
antibodies decline over time, the availability of endogenous GnRH increases and treated ani-
mals generally regain normal fertility [13–17].
Gonadotropin-releasing hormone as an immunocontraceptive in free-ranging horses
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The GnRH-based contraceptive agent known as GonaCon-Equine (National Wildlife
Research Center, Fort Collins, CO, USA; [18] is registered by the United States Environmental
Protection Agency as a restricted-use pesticide for contraception of adult female feral horses
and burros. A single immunization with this or earlier versions of this vaccine (more generally
referred to as GonaCon) have been shown to induce extended infertility ( 2 yr) in numerous
wild ungulate species including captive and free-ranging elk (Cervus elaphus) [15–17] white-
tailed deer (Odocoileus virginianus) [18–20], bison (Bison bison [21]), and feral horses [22– 24].
However, multiple years of infertility are only experienced in a fraction of vaccinated animals.
In free-ranging elk, for example, there was approximately a 90% treatment effect the first year
after vaccination but this declined to 50% by the second year; with no measurable effect by
year three [16]. Similar declines in effectiveness have been reported for captive feral horses
treated with the same vaccine [22].
Booster vaccinations generally result in a more profound and longer-lasting antibody pro-
duction due to the anamnestic (cell memory) response [25]. Traditional veterinary vaccinology
suggests that non-replicating vaccines most often require two initial doses 2–6 weeks apart fol-
lowed by booster vaccinations every 1–3 years [26]. Repeat immunizations using a variety of
GnRH vaccines in domestic horses improves contraceptive efficacy and suppress behavioral
and physiological estrus [27–29]) However, these GnRH vaccines differ from GonaCon-
Equine in that they incorporate different protein carrier molecules and adjuvants, and are for-
mulated for short duration (< 1 yr.) effectiveness. They are also administered on a more tradi-
tional vaccination schedule with a primary set of immunizations followed by periodic
boosters.
Other forms of wildlife fertility control vaccines have adopted comparable initial and
booster recommendations [30–32]. However, this intensive vaccination schedule places signif-
icant logistical barriers on application in free-ranging animals. GonaCon vaccine is formulated
with highly immunostimulating mycobacteria as a component of the adjuvant. This may pro-
long the initial and subsequent booster vaccination windows for optimum efficacy as initial
antibody concentrations are maximal 2–12 months post-primary vaccination [15]. GonaCon
vaccine is one of the rare exceptions among animal vaccines in that the formulation initiates
high antibody titers that remain elevated in some individuals after a single-injection ; however,
little research has been conducted to evaluate booster doses of this vaccine in any free-ranging
wild ungulate [17, 24] or domestic species [33]. While a single immunization against GnRH
may be preferred from a practical perspective, there may be a more optimal vaccination sched-
ule that balances the need for minimizing animal handling or contact while maximizing vac-
cine effectiveness. Thus, it’s imperative to investigate the safety and long-term effectiveness of
repeat vaccination and to evaluate its potential to limit fertility in this long-lived and perenni-
ally pregnant species.
In female wild ungulates, adverse side effects following a single immunization against
GnRH appear to be minimal. Evaluation of biological side effects has been reported for numer-
ous wild ungulate species including white-tailed deer [13, 34], elk [15, 16, 35], feral pigs [36],
bison [21], and free-ranging horses [17, 24]. A summary of results from these investigations
indicate that GonaCon is reversible, safe for use in pregnant females, does not significantly
change social behaviors [37] or negatively affect neonatal development, survival, or maturation
[15, 35]. No adverse effects of vaccination have been shown to be related to general health,
body condition, blood chemistry parameters, or hematology of treated animals. The most
apparent pathological side effect has been the development and persistence of non-debilitating
granulomatous and often purulent inflammation at the site of injection. In all studies, where
post-mortem examinations have been conducted, injection-site lesions were pervasive, but in
some species, such as white-tailed deer and elk, they were not apparent antemortem. Likewise,
Gonadotropin-releasing hormone as an immunocontraceptive in free-ranging horses
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in cases where injection-site reactions have been documented, no clinical evidence of lame-
ness, impaired mobility, or depression, have been reported [13, 15–17, 21, 24, 34, 35].
While documentation of contraceptive efficacy and side effects of GonaCon have been
described for a variety of wild ungulates, similar evidence for feral horses is limited. To our
knowledge, only two long-term ( 3 years) empirical investigations have been conducted
using GonaCon-Equine. These include a clinical trial with captive feral mares [22] and the
other with free-ranging mares in a natural environment [23]. In the study with free-ranging
horses, vaccination significantly reduced foaling rates of treated females, however, effective-
ness was inconsistent over time and was substantially lower than that reported for captive feral
mares treated with the same vaccine [22]. Furthermore, neither of these studies integrated
revaccination as a strategy to increase vaccine efficacy. Lastly, these inquiries provide little
quantitative evidence of the reversibility of the effects of this vaccine, the presence or absence
of adverse side effects related to inoculation of pregnant mares, and neither examined the
potential for increased side effects with reimmunization.
Knowledge of the effects of GonaCon-Equine on equid fetal health, neonatal survival, and
body condition is largely anecdotal, whereas injections site reactions to booster immunization
and the efficacy of revaccination are limited to two investigations [24, 33]. Clearly, additional
research is needed to further define the long-term therapeutic effectiveness and contraindica-
tions of this potential technology before resource managers can make informed decisions
regarding its practical application for stabilizing the growth rate of free-ranging feral horse
populations.
Consequently, the fundamental objectives of this investigation were: 1) to determine the
duration, effectiveness, and reversibility of both a single immunization and subsequent reim-
munization against GnRH in suppressing reproductive rates of free-ranging mares in a natural
environment, 2) to determine the safety and adverse side effects (if any) in free-ranging mares
including assessment of general health, body condition, effects on current pregnancy, injection
site reactions, and neonatal health and survival and, 3) to compare the effects of a single vacci-
nation against GnRH on time budgets and social behaviors [37] to similar behaviors following
reimmunization. Based on evidence from prior studies with feral horses and other wildlife spe-
cies, we predicted (H1:) that a single vaccination against GnRH would suppress fertility for
multiple years with decreasing effectiveness over time but would not result in permanent infer-
tility. Furthermore, we surmised (H2:) that the anamnestic immune response to revaccination
would be more effective and longer lasting in suppressing fertility than the initial immuniza-
tion alone. Moreover, we reasoned (H3:) that except for localized inflammatory reactions at the
injection site, we would not observe other adverse side effects (i.e. lameness, detrimental effects
on existing pregnancy, neonatal health and survival, body condition, behavioral changes).
Apart from determination of return to normal fertility of treated mares, these objectives and
hypotheses were addressed and accomplished in this investigation.
Materials and methods
Study area
We conducted this research in the South Unit of Theodore Roosevelt National Park (THRO),
USA) (45˚ 55’N/103˚ 31’W). This unit is located near the town of Medora in southwestern
North Dakota and encompasses approximately 19,000 ha of native vegetation. The landscape
is topographically diverse and consists of eroded badlands with gullies and ravines separated
by relatively large upland plateaus and small erosion-resistant buttes capped by scoria. Eleva-
tion ranges from 683 m to 870 m. Its continental climate is characterized by short, arid sum-
mers (mean temperature 210 C) and long, cold winters (mean temperature -120 C) [38].
Gonadotropin-releasing hormone as an immunocontraceptive in free-ranging horses
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Precipitation is irregular in amount and distribution with a long-term annual mean of 38 cm
with most of this falling as rain showers from April to June [39].
Vegetation is primarily mixed-grass prairie dominated by needle-and -thread grass (Hesper-
ostipa comata), western wheatgrass (Pascopyrum smithii), threadleaf sedge (Carex filifolia),
blue gramma (Boutelous gracilis), and little blue-stem (Schizachyrium scoparium). Cottonwood
(Populus deltoides) gallery forests occur along perennial water courses while hardwood stands
of green ash (Fraxinus pennsylvanica) and chokecherry (Prunus virginiana) dominate the
upland drainages. Dense stands of Rocky Mountain juniper (Juniper scopulorum) are common
on steep north-facing slopes [40].
Besides feral horses, sympatric wild ungulate species include bison, elk, mule deer (Odocoi-
leus hemionus), white-tailed deer, and pronghorn (Antilocapra americana). Horses and bison
are confined to the South Unit of the Park by a 1.8–2.4 m woven-wire boundary fence. Cur-
rently, horse numbers are controlled through periodic live capture and removal of select indi-
viduals. Free-ranging horses at THRO are classified by the National Park Service (NPS) as
“feral livestock” and managed as a “historical demonstration herd”. The most recent estimate
of population size (2017) is 150–175 horses and the Park has set a management goal for this
herd at approximately 50–90 animals.
The social structure of this population consists of 14–16 social groups (bands) that include
a single dominant stallion, subdominant stallions, and 1–5 adult mares, yearlings, and foals of
both sexes. Males greater than 1 year of age that have not acquired a band are usually found in
ephemeral bachelor groups of 3–6 individuals. These bands are non-territorial and are spatially
distributed across the South Unit primarily east of the Little Missouri River. All horses are
known by unique coloration and markings and have been previously identified and assigned
individual identifiers by managers. Photographs of each animal from birth to adulthood assist
in the identification of individuals. Age, reproductive history, and genealogy data for each ani-
mal has been maintained since 1993.
In spring/summer 2009, we collected pre-treatment data on all mares and bands within
THRO. The purpose of this effort was: 1) to determine the sample size and sampling intensity
required to achieve acceptable statistical power ( 80%) to detect fixed differences ( 50%) in
foaling proportions of experimental groups, 2) to assess unknown logistical limitations of
locating and identifying specific study mares within bands of horses, and 3) to train field tech-
nicians to observation protocols, and collect pre-treatment time budget and social behavioral
data.
Experimental animals and treatments
Primary vaccination (2009–2013). During a scheduled management roundup at THRO
(18–23 October 2009), 160 horses were guided by helicopter into permanent corrals and han-
dling facilities. An attempt was made to capture the entire population to maximize sample
sizes for this research project and to remove excess horses to meet desired herd management
objectives. A total of 57 adult mares (2–17 years of age) and associated foals, and band stallions,
were captured, identified, treated, and retained in the Park for this experiment. Using a ran-
domized complete block design, we established two experimental groups consisting of a Gona-
Con-Equine treatment group (n = 29) and a saline control group (n = 28). Mares were paired
(blocked) based on age and pregnancy status such that animals within a block were as similar
as possible. Within each block, individual mares were then randomly assigned to either a con-
trol or treatment group.
Equine veterinarians and a reproductive specialist, blinded to treatment status, assessed the
general health, body condition, pregnancy status, and approximate gestational stage of each
Gonadotropin-releasing hormone as an immunocontraceptive in free-ranging horses
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mare. We determined pregnancy status and gestational age by transrectal palpation and ultra-
sonography of the reproductive tract [41]. We collected whole blood (up to 50 mL) via jugular
venipuncture (BD Vacutainer SST; Becton Dickinson and Co., Franklin Lakes, NJ) then centri-
fuged these samples at the capture site, and temporarily stored serum in cryovials at -200 C.
We later transferred frozen serum on dry ice to Fort Collins, Colorado, where it was stored at
-800 C. We also assessed serum for exposure to common pathogens known to cause abortions
in horses (e.g. equine herpesvirus-1, equine infectious anemia, equine viral arteritis and conta-
gious equine metritis) that could confound the interpretation of treatment-induced infertility
[42].
We applied treatments while mares were restrained in a squeeze chute. Females in the treat-
ment group received an intramuscular injection in the lower left gluteal musculature, by hand-
held syringe (18-gauge, 3.8 cm needle) containing GonaCon-Equine (2.0 mg GnRH conjugate
+ adjuvant; 2.0 mL). The vaccine contained multiple synthetic copies of GnRH coupled to a
large immunogenic carrier protein (Blue Carrier; Biosonda, Santiago, Chile) that was com-
bined with a water-in-oil adjuvant containing killed Mycobacterium avium ssp. avium (Adju-
Vac, National Wildlife Research Center) [18]. Mares in the control group were injected in a
similar manner, with an equal volume of physiologic saline solution (0.9% NaCl; 2.0 mL). We
chose to inject the vaccine into the gluteus muscle (~ 15 cm distal to the point of the hip) rather
than the neck because of greater safety for hand-injection, enhanced detection of potential
injection site reactions under field conditions, and the preferred location for potential remote
dart delivery of the vaccine.
Secondary vaccination (2013–2017). Four years later, during 23–25 September 2013, we
similarly rounded up the entire THRO horse population and moved and handled them
through existing corrals and chute systems to remove excess animals from the Park. Given this
unique opportunity and endorsement from the Park, we retained all available mares previously
immunized and control mares, retreated them, assessed pregnancy status, and determined
body condition using techniques identical to those applied at the 2009 roundup. Two mares in
the control group and 4 mares in the treatment group died between 2009–2013 and therefore,
were not available for this experiment. We attributed these mortalities to malnutrition, dysto-
cia, broken appendage, and unknown causes not related to treatments. The one exception in
our 2013 protocol was that we injected the booster vaccination into the opposite (right) hip
from where the primary (left hip) vaccination was previously administered. This provided the
opportunity to simultaneously evaluate injection site reactions related to both immunizations.
Treatment mares again received 2.0 mL GonaCon-Equine and control mares 2.0 mL saline.
Field measurements
Using 2–3 trained technicians and occasional equally trained volunteers, we conducted field
measurements and observations consistently from year to year. Prior to field observations,
technicians were provided with photographic images of individual horses and required to rec-
ognize them by band association, natural markings, and pelage coloration. They were also
trained or had previous experience in identifying prepartum characteristics of pregnancy (e.g.,
enlarged abdomen, mammary gland development, waxing teats, behavior, etc.), as well as,
body condition scoring, and the appearance and classification of injection site reactions to the
vaccine. We collected all data from ground surveys (foot, vehicle, horseback) using binoculars
and spotting scopes. Although technicians were unaware of treatment assignments of individ-
ual mares, the presence of injection site reactions in several GonaCon-treated mares could
have revealed their treatment designation.
Gonadotropin-releasing hormone as an immunocontraceptive in free-ranging horses
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Reproduction. We predicted that pregnant females inoculated with GnRH at the fall gath-
ers of 2009 and 2013 would give birth to a healthy foal the following spring (2010 or 2014) and
presumably be infertile during subsequent breeding seasons. Thus, the effects of the primary
or booster vaccinations on reproduction (foaling proportions) would not be observed until the
2011 and 2015 foaling seasons, respectively. These are the first breeding seasons that a treat-
ment or retreatment effect on mare fertility could be detected when using foaling observations
to assess successful contraception by the vaccine.
We determined the effectiveness, duration of effects, and reversibility of the primary and
booster vaccinations on reproduction by comparing foaling proportions of treated and control
mares during 1 March to 31 December 2009–2017. We chose to use the term vaccine “effec-
tiveness” rather than “efficacy” because it more realistically represents how GonaCon-Equine
affects fertility under more natural field conditions compared to a controlled clinical trial [43,
44]. We defined vaccine effectiveness (VE) as the proportional reduction in annual foaling
(F = number of mares with a foal/ total number of mares in a treatment group) between con-
trol and treated mares. Vaccine effectiveness is equivalent to relative risk reduction (RRR) in
medical statistics and was calculated from the risk ratio RR ¼ FTrtFCon
 
where FCon = foaling pro-
portion of the control mares, and FTrt = the foaling proportion of the treated mares. Risk ratio
was calculated using the fmsb package in program R [45–47] and we then solved for VE as fol-
lows:
VE ¼
FCon   FTrt
FCon
¼ 1  
FTrt
FCon
¼ 1   RR
Each year of the study, we estimated annual foaling proportions by locating all bands to
identify individual mares and determine the presence or absence of foals. During the intensive
sampling period (1 March–1 August), we attempted to observe 95% or greater of all experi-
mental mares and foals (when present) at least weekly and 100% of them every two weeks,
then opportunistically until 31 December. We did not attempt to assess contraceptive effect
based on visual characteristics of pregnancy but did use these criteria to prioritize weekly
observations of individual mares. Instead, we defined foaling as a parturition event or neonatal
foal by side, as detected by direct observation. We matched foals with dams through observa-
tions of nursing and repeated close association during feeding, bedding, and traveling [48, 49].
We collected neonatal data at first sighting of a foal and estimated date of birth by observing
the foal’s level of activity, presence of an umbilicus, and elapsed time since the dam was last
observed pregnant [50]. We photographed and estimated the age of each new foal when first
observed, recorded its sex, general health (vigorous, average, poor), markings, and band asso-
ciation, and gave it a unique identifier; then entered these observations into a herd database.
Finally, we assessed the utility of using foaling proportions as a proxy for pregnancy propor-
tions by comparing pregnancy proportions determined at the time of each gather in 2009 and
2013 to foaling proportions observed in 2010 and 2014.
Side effects
Behavioral. We repeated thee behavioral measurements with the same treatment groups
of mares that were previously conducted during an earlier phase of this project [37]. We pro-
posed that, if greater contraceptive effectiveness after reimmunization against GnRH was
achieved, it would potentially provide a larger and more statistically powerful sample size of
contracepted animals in which to detect behavioral changes related to this vaccine (if they
occurred).
Gonadotropin-releasing hormone as an immunocontraceptive in free-ranging horses
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We completed an intensive behavioral study during an earlier phase of this larger GnRH
study during 2009–2010 [37]. To make these analyses directly comparable to that prior study,
we followed the same behavioral sampling design as that described previously [50]. Briefly, this
included blocking observations into three daylight time periods (08:00–12:00 h, 12:01–16:00 h,
and 16:01–20:00 h) with observations conducted during the primary breeding season, 1
March– 1 August 2014. Each observation session included collection of a 20-min instanta-
neous scan sample of time budgets at 1 min intervals for each adult band member (1 year
old), and all-occurrence data collection for social interactions [37].
Primary behavior categories included feeding, resting, locomotion, maintenance, and social
behaviors [51]. Social behavior data included herding, reproduction, agonism, harem-tending,
and harem-social behavior, and were collected at all occurrences throughout the observation
sessions. Harem-social behavior was not collected through all-occurrence sampling in our pre-
vious study; however, it was collected during the scan sample in the previous study and was
worthy of further consideration here. We defined this category as interactions between two
individuals that did not meet the definition of the other all-occurrence behaviors (e.g. allo-
grooming and non-reproductive olfactory investigation).
We observed all horses from the nearest distance that did not elicit attention to the presence
of the observer, typically 50–200 m. All observations were conducted using a 15–45 × 600 mm
spotting scope or 10 × 42 mm binoculars when the distance between horses and observers was
too far to allow unassisted detailed observation. We observed each band of horses weekly or
bi-weekly in conjunction with other field assessments.
Physiological. Concurrently with foaling and behavior observations, we evaluated and
compared potential adverse side-effects of treatment on injection-site reactions, body condi-
tion, success of existing pregnancy, and neonatal survival in treated and control mares. We
made assessments of these potential side-effects monthly during the primary foaling season
and opportunistically for the remainder of the year. We observed each mare for the presence
or absence of visible lesions, swellings, or discharge at the injection site. In addition, we docu-
mented evidence of lameness (e.g. limping, gait alteration, reluctance to stand or bear weight
on a limb), as well as behavioral depression, muscle tremors, or other systemic reactions that
could be related to the vaccine treatment. We classified injection-site reactions according to
the following criteria: 1) abscess–an open sore usually with fluid drainage or discharge, 2)
swelling–a raised area of tissue of variable size and shape with no visible fluid drainage, 3)
lameness–any abnormal range of movement or stiffness in the leg where the vaccine injection
was delivered, 4) none–no observable reaction [52]. These categories were not mutually exclu-
sive with respect to a single observation and both sides of the animal were observed, when pos-
sible. For these observations, we approached as near as possible to individual horses ( 50 m)
and assessed and photographed each injection-site reaction for later evaluation. At the same
time, we visually evaluated body condition of each mare and scored condition as previously
described [53]. We evaluated the success of the existing pregnancy by comparing foaling pro-
portions between treated and control groups in 2010 and 2014. We measured neonatal survival
as the proportion of foals surviving to 14 days of age and post-natal survival to 200 days.
Statistical analysis
Reproduction. Yearly foaling data are reported as the proportion of mares observed with
a foal in each group. We used asymptotic approximation to the binomial distribution to com-
pute 95% confidence intervals for these proportions using package binom in program R [45,
47]. We used a risk ratio analysis (α = 0.05) to compare all observed annual proportions
between treatment groups. We used the same method to evaluate the success of the existing
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pregnancy between groups during the first foaling season post-vaccination (2010 and 2014).
All comparisons between treatment groups were made within a single year and without multi-
ple testing corrections.
Behavior. We used the same statistical approach for the analyses in 2014 as that used in
2010 [37]. We modeled the frequency of each behavior using mixed-effects linear regression,
where individual female identity and sampling time (time of day) were included as random
effects on the intercept term of each model. This accounted for variation that may have been
present among individuals who were sampled repeatedly, though not always equally over time,
and for temporal variation in behavior when samples were not equally collected across all
times of the day. Time budget behaviors sampled at 1-min intervals were aggregated into pro-
portion of time spent per behavior to calculate an independent measure of behavior per obser-
vation session. We used the lme4 package of R version 3.1.2 (The R Foundation for Statistical
Computing 2014) and SYSTAT 12.02.00 (SYSTAT Software, Inc. 2007) to calculate descriptive
statistics and obtain mixed-effects model estimates using restricted maximum likelihood [54].
Separate models were fitted for each time budget behavior with the fixed effects of treatment
group (treated or control), foal presence (dependent foal < 1 year of age present with the
female, or no foal present with the female), female age, and band size. In the previous study,
we considered band fidelity (number of times a female moved bands within a year), but data
were too homogeneous to consider that factor in 2014: only 8 horses moved bands at all (4
treated/4 saline) and five of those moved collectively to a different stallion.
Physiological. We used descriptive statistics (arithmetic means with ± 95% CI) to com-
pare, occurrence of lesions at the injection site and 1-tailed Fisher’s exact test (α = 0.05, 1df) to
compare foal survival proportions of treated females to that of controls. We used normal bino-
mial distributions to compute confidence limits for the differences between proportions using
Jeffrey’s interval for small sample sizes [55]. Effects on body condition scores were examined
using generalized linear models in the lmer package in program R [56]. We employed random
effects for year and individuals and then compared this nested model to full models which
added the effect of either treatment or foaling using an ANOVA.
This research was approved by the Institutional Animal Care and Use Committees of the
National Park Service (NPS) (Permit Numbers: MWR_THRO_Baker_Horse_2013.A3,
MWR_THRO_Baker_Horse_2015.A3) and Colorado State University (IACUC Protocol No.
17-7651A). This study was conducted in accordance with good laboratory practices (GLP) and
oversight from United States Department of Agriculture/National Wildlife Research Center
(No.QA1647). All data collections were conducted after obtaining a scientific collection permit
issued by Theodore Roosevelt National Park (THRO-2010-SCI-0010). All work, other than
animal handling and vaccination at the two feral horse roundups, was observational. Every
effort was made to prevent and minimize disruption of natural band dynamics and individual
horse behavior and well-being during handling and treatment application.
Results
The statistical process used to select experimental mares for this investigation resulted in two
treatment groups that were relatively homogeneous in age, body condition, body mass, and
pregnancy status [S1 Table]. Results of pregnancy assessment indicated that most mares were
pregnant at the 2009 (0.86 (49/57), 95% CI = 0.74–0.93) and 2013 (0.90 (46/51), 95%
CI = 0.79–0.96) roundups, thus providing sufficient opportunity to evaluate and compare the
safety and potential side effects of vaccine treatment on pregnancy and neonatal survival.
Transrectal ultrasonography revealed that the fetuses of most pregnant females were
approximately 120+ days old at the roundup and that most had descended over the pelvic rim
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preventing a more accurate assessment of gestational age at treatment application [57]. To pro-
vide a more precise estimate, we used an estimated gestation period for horses of 342 days [58]
and the approximate foaling date (± 5 days) of each mare in 2010 and 2014 and then back-cal-
culated to the date of treatment application at the 2009 (18–23 October) and 2013 (23–25 Sep-
tember) roundups. Using these calculations, we estimated mean gestational age at vaccine
inoculation in 2009 to be 162 days (95% CI = 150–175) for treated mares and 154 days (95%
CI = 138–170 days) for control mares. For 2013, we used the same calculation and projected
that, on average, females were reimmunized against GnRH at approximately 129 days (95%
CI = 105–151 days) of gestation and saline-treated control mares at 132 days (95% CI = 119–
144 days).
Following the 2009 and 2013 roundups and release, experimental mares distributed them-
selves among 16–19 individual bands. At least one treated or control mare was present in all
bands during 2010–2017. Likewise, the composition of adult mares in each band, as well as the
band stallions, remained relatively stable during this period. By the end of the 2017 foaling sea-
son, 14% (4/29) of treated mares and 11% (3/28) of control mares had died of various causes
(e.g., malnutrition, broken appendage, dystocia, unknown causes). Except for these mares and
one vaccinated mare that was not re-captured at the 2013 gather, all others were observed for
foaling and other field measurements for all eight years of this investigation.
We met our sampling objective by observing more than 95% of all mares weekly (and some-
times more often) from 1 March to 1 August each year of the study. It is possible that some
foals were born and died without being detected but given the intensity of the sampling obser-
vations, we feel that this was highly unlikely. Observations during the remainder of the year
and following winter were less intense and more opportunistic depending upon available per-
sonnel, weather, and road conditions. During this time, mortality of foals was more likely to
have gone undetected.
Vaccine effectiveness
Primary vaccination (2009–2013). Mean foaling proportions of treated (0.62 (18/29)
95% CI = 0.44–0.79) and control (0.68 (19/28) 95% CI = 0.50–0.85) mares during the 2009
pre-treatment foaling season were not different (P = 0.65) indicating that prior to contracep-
tion, treatment groups exhibited equal fertility [S1 Table]. Further evidence was provided by
individual mares at the 2009 gather and primary vaccine inoculation. The proportion of
treated (0.86 (25/29), 95% CI = 0.71–0.95 and control (0.85 (24/28), 95% CI = 0.70–0.95)
mares determined to be pregnant, via transrectal ultrasonography, were not different
(P = 0.63) [S1 Table, Fig 1]. This provided an opportunity to compare the effects of GonaCon-
Equine vaccination on the existing pregnancy of treated mares and neonatal health and sur-
vival to that of untreated control mares. Foaling proportions of treated (0.68 (19/28) 95%
CI = 0.50–0.85) and control (0.64 (18/28), 95% CI = 0.46–0.82) mares during 2010 were not
different (P = 0.78) (Fig 1). Births occurred from early March to early September with 97%
(35/36) observed during the first four months of the foaling season (1 March to 1 June). Aver-
age foaling dates in 2010 for treated and control mares were 5 May (95% CI = 22 April–18
May) and 10 May (95% CI = 25 April–25 May), respectively. No foal was detected for 12 mares
(6 treated: 6 control) that were determined to be pregnant at the 2009 gather. None of these
mares showed evidence of pregnancy during the intensive foaling period or for the remainder
of the year. We surmised that most of these foals were either aborted or died as neonates
between the periods from 20 October 2009 (gather) to 1 March 2010 (beginning of foaling
observations). Regardless of timing or cause of death, the proportion of mares that foaled in
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2010 underestimated the proportion of mares that were determined to be pregnant at the 2009
gather by 24% for treated mares and 21% for control mares.
Estimated age of all foals at first observation was 2.4 days (95% CI = 1.7–3.1days). Most
neonates (97%), from both experimental groups, were classified as vigorous and in good to
excellent condition when first observed. Neonatal survival rate from parturition to 14 days of
age was estimated to be 0.95 (18/19, 95% CI = 0.75–0.99) for foals born to GonaCon-treated
females and 0.88 (16/18, 95% CI = 0.64–0.98) for foals born to control mares (P = 0.54). After
14 days of age, post-neonatal survival rates (14–200 da) averaged 0.97 (30/31, 95% CI = 0.84–
0.99) and were similar for both experimental groups (P = 0.57). These results support our pre-
diction (H3) that inoculation with GonaCon-Equine vaccine, during approximately the second
trimester of pregnancy, does not affect the existing pregnancy of treated females or neonatal
health and survival.
The proportion of treated mares that foaled (13/28) following a single vaccination was
lower than that for control mares (19/26) for the second (2011) (P = 0.04) and third (15/27 vs
21/27) (2012) (P = 0.08) post-treatment foaling seasons but was similar (18/26 vs (18/27)
Fig 1. Comparative probability of foaling and pregnancy for treatment and control groups of free-ranging feral horses (Equus
caballus)mares selected for this experiment. Mares were treated with a primary vaccination of GonaCon-Equine in October 2009 and
then reimmunized with the same vaccine in September 2013 at scheduled gathers at Theodore Roosevelt National Park, North Dakota,
USA. GonaCon vaccinations occurred at the time points represented by the red arrows. Symbols correspond to observed p-values for
relative risk comparisons between treatment groups within years (p-value between 0.05 and 0.1 = +, for< 0.05 = x, and for< 1x10-05 = ).
https://doi.org/10.1371/journal.pone.0201570.g001
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(P = 0.67) to control mares for the fourth (2013) season, demonstrating reversibility of the pri-
mary vaccine treatment (Fig 1). Even though we observed a significant reduction in foaling
proportions between treated and control mares during 2011 and a declining effect in 2012,
therapeutic effectiveness and relative risk reduction estimates were low to modest and esti-
mated to be 0.37 (95% CI = 0.01–0.60) and 0.28 (95% CI = -0.06–0.51), respectively (Table 1).
These findings lend support to our hypotheses (H1) that a single vaccination with GonaCon-
Equine is reversible and suppresses fertility for multiple years post-treatment in a portion of
treated animals but with diminished effectiveness over time.
Secondary vaccination (2013–2017). At the scheduled gather in October 2013, we
extended our evaluation of GonaCon-Equine by assessing the effects of revaccination on fertil-
ity and safety in these same experimental mares treated four years after the primary vaccina-
tion. Evidence of similar fertility for individual mares was demonstrated at the 2013 gather,
where pregnancy proportions of treated (0.92 (23/25), 95% CI = 0.75–0.98) and control (0.88
(23/26), 95% CI = 0.71–0.96) mares were similar (P = 0.86) [S1 Table]. Except for one treated
and one control mare, all others had conceived and given birth to at least one foal during
2009–2013. For the 2013 foaling season, foaling proportions of treated (0.69 (18/26), 95%
CI = 0.51–0.87) and control (0.66 (18/27) 95% CI = 0.49–0.84) mares were not different
(P = 0.84) providing additional evidence that treatments groups were of equal fertility prior to
reimmunization (Fig 1).
Like 2010, mean foaling proportions during the first post-treatment foaling season (2014)
were not different (P = 0.74) between treated (0.60 (15/25), 95% CI = 0.41–0.79) and control
(0.56 (15/27), 95% CI = 0.37–0.74) mares (Fig 1) supporting similar observations in 2010 that
revaccination could be applied to pregnant mares, during mid-gestation, without risk to the
existing pregnancy. Foaling date distribution was comparable to that observed in 2010 follow-
ing the primary vaccination. Average foaling date for treated mares was estimated to be 27
April (95% CI = 5 April– 20 May) and 19 April (95% CI = 6 April– 2 May) for controls. No
foal was observed for 15 mares (8 treated: 7 control) that were determined to be pregnant at
the 2013 gather. Like 2010 estimates, foaling proportions underestimated pregnancy propor-
tions determined at the 2013 gather for both treated and control mares by approximately 30%
and 34%, respectively (Fig 1). These data, together with similar observations in 2010, support
the inference that foaling proportions are not an accurate proxy for pregnancy proportions but
provide a limited but practicable field measurement for determining contraceptive
Table 1. Comparative relative risk reduction (RRR), 95% confidence intervals, and p-values associated with differ-
ences in foaling proportions between GonaCon-treated and control mares during 2009–2017.
Year Relative Risk Reduction 95% Confidence Interval p-value
(RRR) Lower Upper
2009 0.0852 0.3757 -0.3402 0.6500
2010 -0.0555 0.2750 -0.5301 0.7797
2011 0.3732 0.6028 0.0109 0.0381
2012 0.2857 0.5178 -0.0581 0.0861
2013 -0.0384 0.2826 -0.5032 0.8430
2014 -0.08 0.3216 -0.7194 0.7482
2015 1 1 NA 2.57E-09
2016 0.8095 0.9236 0.5247 1.94E-06
2017 0.9451 0.9920 0.6217 4.15E-07
Significant p-values (<0.05).
https://doi.org/10.1371/journal.pone.0201570.t001
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effectiveness. Average foal age at first observation across both treatment and control groups
was 2.6 (95% CI = 1.5–3.3) days. Nearly all foals born to revaccinated and control mares were
classified as vigorous and found to be in good to excellent condition when first observed.
Neonatal survival rate to 14 days of age for foals born to revaccinated mares was 0.87 (13/
15), 95% CI = 0.62–0.96 and 0.93 (14/15), 95% CI = 0.70–0.98) for foals born to control mares
(P = 0.49). After 14 days of age, post-neonatal survival rates were 0.80 (12/15), 95% CI = 0.55–
0.92) for revaccinated mares and 0.73 (11/15), 95% CI = 0.48–0.89) for control mares (P =
0.55). These results reflect similar findings following a primary vaccination with GonaCon-
Equine and reinforces the deduction (H3) that reimmunization is safe for treatment of preg-
nant females and does not affect neonatal or post-neonatal health or survival when applied at
approximately mid-gestation.
Unlike results from the single vaccination trial, we observed, not only highly significant
reduction in foaling proportions between treated and control mares following reimmunization
but also a remarkably effective contraceptive response. Except for the first foaling season fol-
lowing treatment application, (2014) in which the vaccine was not expected to have an effect
(P = 0.75), foaling proportions in reimmunized mares were lower (P<0.001) than that for
control mares for all subsequent years (2015–2017) (Fig 1). This was particularly evident for
the second post-treatment foaling season (2015) when none 0.00 (0/25), 95% CI = 0.0) of the
reimmunized mares produced a foal while the proportion of control mares foaling was esti-
mated to be 0.84 (21/25, 95% CI = 0.69–0.98). During the third post-treatment foaling season
(2016), four treated mares produced a foal resulting in a foaling proportion of 0.16 (4/25), 95%
CI = 0.01–0.30) while the proportion of control mares foaling was identical to that observed in
2015 (Fig 1). These foals were determined to be vigorous and in good to excellent condition at
birth, however, two of these foals, born in September, were not observed the following spring
and were categorized as post-natal mortalities and presumed to have died during winter
(2016/2017).
In 2017, no additional treated mares produced a foal or showed evidence of pregnancy.
However, one of the treated mares that had foaled in 2016 died of apparent natural causes
(age-related malnutrition) during 2017 and two other revaccinated mares that had foaled in
2016 failed to produce a foal that year resulting in a foaling proportion of 0.041 (1/24), 95%
CI = 0.03–0.12) (Fig 1). The foaling proportion for mares in the control group (2017) was 0.84
(21/25, 95% CI = 0.69–0.98) and higher (P<0.001) than that for GonaCon-treated mares (Fig
1). It should be noted that the apparent decrease in foaling proportions in GonaCon-treated
mares from 2016–2017 and resulting increase in vaccine effectiveness (Table 1) is likely due to
the inherent error associated with the small sample size (n = 4) of mares in this treatment
group that regained fertility. Overall, there was both a substantial decrease in foaling propor-
tions (Fig 1) and an exceedingly high level of effectiveness (Table 1) for treated mares com-
pared to controls for 3 years post-revaccination (2015–2017) (P<0.001). Thus, fertility
measurements during 2015–2017 support our prediction (H2) that revaccination with Gona-
Con-Equine would be more effective in suppressing foaling proportions in treated females
compared to controls than a single immunization (Fig 1, Table 1).
Side effects
Behavioral. We collected behavioral data on 73 feral horses (22 males, 25 treated females,
26 saline females) for 218.3 h in 2014. The median age of observed stallions was 12 years
(range = 9–19 years), median age of observed control females was 8 years (range = 7–20),
median age of observed treated females was 9 years (range = 7–22), and median band size was
8 horses (range = 2–14). There were no differences detected between treatment groups in any
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time budget behavior category (Table 2). As band size increased, feeding decreased 1.24%
(95% CI = 0.48–2.00) per additional horse in the band. Likewise, locomotion increased 0.20%
(95% CI = 0.07–0.33) and maintenance decreased 0.10% (95% CI = 0.01–0.19) per additional
horse in the band.
Foal presence influenced locomotion, with barren females moving 1.24% (95% C I = 0.40–
2.08) more than females with dependents. Foal presence also influenced the social behavior
component of time budgets, with barren females interacting with others 2.74% (95%
CI = 0.59–4.90) more than females with dependents.
Variance among individuals had little influence on any of the behaviors modeled (Table 2).
Variance was also minimal between time periods of observation; however, there were some
significant differences in amount of activity by time of day. An estimated 6.88% (95% C I =
-0.73–14.5) more feeding occurred in the 1601–2000 h time-period than did earlier in the day,
and this was reciprocated by an estimated 3.33% (95% CI = 1.09–7.79) less resting, 0.34% (95%
CI = 0.15–0.82) less maintenance, and 1.30% (95% CI = 0.51–3.11) less social behavior during
the same period.
There were no differences detected between treatment groups in herding, reproduction, or
agonism, but treatment group did influence harem-social behavior. Observed instances of
harem-tending behavior provided too few data to model. Because these social behaviors were
not as dependent on other broad categories as is the case with compositional time budgets
[51], we re-estimated the social behavior models with only treatment and supported effects to
allow for clearer interpretation of the results.
Stallions initiated harem-social behavior 13.9% (95% CI = 3.25–24.68) less toward control
females than toward treated females. Though all harem-social records were analyzed as a
group, it should be noted that 55.8% of the 308 harem-social events were sub-categorized as
allogrooming. While the significant difference between treatment groups was detected, the
variance among individuals for this behavior was near zero (Table 2).
Physiological. No study mares exhibited antibody titers to any of the infectious diseases
that were surveyed for (i.e., equine herpesvirus-1, equine infectious anemia, equine viral arteri-
tis and contagious equine metritis) thus eliminating this factor as a potential cause of infertility
in GonaCon-treated females.
No control mares, treated with saline, showed any evidence of injection site reactions.
Swelling and discharge were never observed in this group. Likewise, these mares showed no
evidence of lameness or gait abnormalities in either hind limb. Consistent with our hypothesis
(H3), approximately 72% of treated mares (21/29) displayed a visible reaction at the site of
injection after a single vaccination with GonaCon-Equine (S1 Photo). A single mare developed
a draining abscess after the initial vaccination. These lesions were persistent over multiple
years. At the time of the 2013 roundup and revaccination, 81% (21/26) of vaccinated mares
continued to have palpable swelling at the original site of vaccine injection.
Like initial vaccination reactions, during the first-year post-revaccination, approximately
50% (13/26) of mares continued to show swelling on the left hip at the site of the 2009 injection
and 50% developed a reaction on the right hip at the site of revaccination in 2013. Two of these
new reactions were draining abscesses. Yet again, injection site reactions were persistent with
approximately half of the mares with swellings at one or both injection sites, 3 years after
revaccination. None of the GonaCon-treated mares displayed any evidence of lameness,
altered gait or abnormal range of movement throughout the 8 years they were observed.
While body condition varied between individuals and study years, it did not vary between
treatment groups (P = 0.14) over the course of the study. Likewise, there was no effect of pres-
ence of a foal on body condition (P = 0.16). Average body condition ranged from 3.7–4.9
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(moderately thin to moderate body condition) for all study animals over the 8 years that mares
were observed. Individual body condition scores ranged from 1–7.
Discussion
Reproduction
This study demonstrated that a single vaccination against GnRH, using GonaCon-Equine,
administered during mid-gestation, was safe, initiated short duration (2 yrs.) infertility in
some mares, and was reversible, but was minimally effective in reducing fertility of treated
females compared to controls. For two foaling seasons following vaccine treatment, we
observed statistically significant reductions (28–38%) in foaling proportions of treated versus
control mares but no effect by the third-year post-treatment, thus confirming the reversibility
of the vaccine.
These results parallel similar findings from other experimental evaluations of GonaCon-
Equine reported for captive and free-ranging mares. In a comparable study in Nevada with
feral horses in a natural environment, GonaCon-Equine reduced foaling proportions by an
average of 33% over a 3-year period but, like our study, contraception was only modestly effec-
tive over this period [23]. In contrast, contraceptive effectiveness of captive mares treated with
GonaCon was greater and longer lasting ( 4yrs) than either of these studies [22]. The dispar-
ity between captive and free-ranging animals in contraceptive response to GonaCon vaccine is
not limited to feral horses but has also been observed between captive and free-ranging white-
tailed deer [14, 18, 20] and elk [15, 16, 19]. Although these investigations did not suggest a
definitive causation for these differences, they all pointed to suppressed and less persistent
GnRH antibody concentrations in free-ranging ungulates compared to their captive counter-
parts suggesting a relatively compromised or weakened immune response to the vaccine that
resulted in reduced contraceptive effectiveness.
It is widely acknowledged that differences in vaccine effectiveness can be attributed to
increased environmental stressors (i.e., nutritional status, injuries, parasite load, pathogen
exposure, and social dynamics) that can inhibit a more vigorous immune response in free-
Table 2. Treatment and supported effects in a mixed-effects linear regression of feral horse (Equus caballus) time budget behaviors (e.g. feeding, resting, locomo-
tion, maintenance, social) and all-occurrence social behaviors (e.g. herding, reproduction, agonism, harem- social) at Theodore Roosevelt National Park, USA. Var-
iance for the random effects of time of day (j) and individual horse identity (k) are shown as σj2 and σk2.
Behavior Effect t P Difference 95% confidence limit σj2 σk2
Lower Upper
Feeding Treatment -0.125 0.900 0.004 0.003
Band Size -3.193 0.001 -0.012 -0.020 -0.005
Resting Treatment 0.590 0.555 0.001 0.001
Locomotion Treatment -0.143 0.886 <0.001 <0.001
Band Size 3.047 0.002 0.002 0.001 0.003
Foal Presence 2.900 0.004 0.012 0.004 0.021
Maintenance Treatment -1.193 0.233 <0.001 <0.001
Band Size -2.238 0.025 -0.001 -0.002 -0.001
Social Treatment -0.037 0.970 <0.001 0.001
Foal Presence 2.499 0.013 0.027 0.006 0.049
Herding Treatment -0.909 0.368 0.009 <0.001
Reproduction Treatment 1.555 0.159 <0.001 <0.001
Agonism Treatment 0.669 0.528 <0.001 0.048
Harem-social Treatment 2.620 0.012 0.140 0.033 0.247 0.007 <0.001
https://doi.org/10.1371/journal.pone.0201570.t002
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ranging animals in a natural environment [59, 60]. It follows that while efficacy trials with cap-
tive animals can provide an important first approximation of vaccine safety and performance
under controlled conditions; they may offer only limited inference to free-ranging animals
that are not buffered against natural stressors that may decrease immune response and vaccine
effectiveness. Regardless of the factor(s) contributing to the limited effectiveness of GonaCon
in free-ranging animals, it appears that the immune response from a single vaccination does
not consistently provide multiple years of infertility in all or even a high proportion of these
animals.
In comparison to a single inoculation with GonaCon-Equine, the effect of reimmunization
on foaling proportions was highly significant which allowed clear differentiation between
treated and control mares for multiple breeding seasons. Compared to a single vaccination,
reimmunization of mares in this study resulted in a much higher (58%) average vaccine effec-
tiveness (range = 0.80–0.94) than the single vaccination for a 3-year period (2015–2017). Like-
wise, this level of effectiveness following reimmunization was on average higher than that
previously reported for free-ranging mares treated with a single application with GonaCon-
Equine [23] and 32% above what was reported for captive mares treated with the same vaccine
formulation [22]. These results support the conclusion that a booster immunization with
GonaCon-Equine can provide a highly effective, multi-year suppression of fertility in free-
ranging horses and these results may be consistent in other animal species, as well.
It is fundamental knowledge that a secondary response to a vaccine generally results in a
more rapid production of antibodies that are produced in greater amounts and over a longer
time compared to the primary vaccination [25]. Repeat immunizations using a variety of
GnRH vaccines in domestic horses have been shown to improve contraceptive efficacy. How-
ever, unlike commercially available short duration vaccines (< 1 yr.) developed for domestic
horses [29, 61], GonaCon-Equine is formulated by combining a non-biodegradable oil in
water-based emulsion and an optimum concentration of immunostimulatory killed mycobac-
teria to form a depot usually deep in muscle tissue. This depot injection is thought to allow for
a slow release and prolonged stimulation so that the formulation can act for much longer peri-
ods of time (years) than is possible with standard injections (months). This effect is thought to
be responsible for the extended antibody response of 3–4 years in vaccinated deer [14, 18, 20,
62], elk [15, 16], and horses [22].
While this response was not unexpected, the magnitude and duration of effectiveness of
GonaCon-Equine following revaccination, even 4 years after the initial vaccination, is salient
and relevant to the management of fertility in free-ranging horses. First, it demonstrates that a
booster vaccination can stimulate a highly effective immune response that can result in multi-
ple years ( 3 yrs.) of contraception. Second, it provides an initial reference point for defining
the optimum revaccination schedule required for long-term reproductive management of
female horses in a natural environment. And finally, it supports the consideration that while a
single application may be preferred from a practical management perspective, GonaCon-
Equine is more effective, in free-ranging horses, if repeat vaccinations are delivered on a peri-
odic basis. While initial results are encouraging, additional research is needed to complete the
objectives of this study including: 1) to define the duration of effective contraception post-
revaccination, 2) to determine if long-term or permanent infertility is a possible outcome, and
3) to assess if return to fertility (if it occurs) results in altered birth phenology of treated mares.
We will investigate these questions over the next three years of this study. Additionally, there
may be a more optimal revaccination schedule which allows for altered duration of effective-
ness or is more conducive to management schedules.
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Side effects
After revaccinated in October 2013, time budget and social behaviors of mares in spring/sum-
mer of 2014 were comparable to those observed during the same period in 2010, following the
initial treatment in October 2009. We found no evidence of differences in frequency or inten-
sity of social behaviors including estrous behavior associated with treatment. Both treatment
and control groups displayed few estrus behaviors in either 2010 [37] or during 2014. Behav-
iors associated with estrus were observed only 17 times in treated and 57 times in control
mares out of 1148 observed social behavior events. This supports our earlier findings that preg-
nant mares rarely show overt estrous-related behaviors and similarly GonaCon-Equine treated
mares only occasionally display these behaviors, although each for different reasons. Once a
mare is pregnant, progesterone likely subverts much of the estrous type behavior that would
generally be displayed with high estrogen levels, and only occasionally do domestic horses dis-
play and stand for mounting when pregnant [63]. Relatively small amounts of estrogen are
secreted as follicles develop and then regress. In the absence of progesterone, relatively small
amounts of estrogen are likely sufficient to induce erratic estrous behavior as was observed in
these mares. However, the small amounts of estrogen were likely insufficient to induce an LH
surge and subsequent ovulation.
Regardless of the underlying endocrinology associated with these behaviors, vaccinated and
control mares both displayed social interactions that maintained herd structure; herding, tend-
ing, and defending behaviors from the stallion; and social hierarchies. The only meaningful
factor that influenced the amount of time spent in social behaviors (e.g. allo-grooming, herd-
ing and tending) was the presence or absence of a foal. Mares with foals spent more time alone
with the foal than those without off-spring, which is to be expected given their social and nutri-
ent requirements during the neonatal and post-natal periods [50]. It is possible that long-term
absence of foals could influence social behavior on a longitudinal scale, but additional studies
are needed to investigate such phenomena on an appropriate time scale.
Other techniques for reducing the fertility of free-ranging species, such as vaccination with
the native porcine zona pellucida vaccine (PZP) and tubal ligation, maintain the competency
of the endocrine aspects of fertility. This can lead to unintended consequences with repeated
estrous cycling in polyestrous species. In fact, in a population of white-tailed deer, where most
reproductive females had received tubal ligations, fawning was negligible; however, there was
more than a 700% increase in the number mature males attracted to the area occupied by a
high number of estrous cycling females [64]. Similarly, PZP vaccination has extended the
length and intensity of breeding seasons in horses [49, 65–68], deer [69, 70], and elk [71].
GonaCon-Equine may avoid these inadvertent consequences by functionally inducing mim-
icry of pregnancy in females which continues to be an important part of the social structure of
the group but does not invite intense adverse breeding behaviors.
Researchers have generally hypothesized that by alleviating the energetic demands of gesta-
tion and lactation, contracepted females will attain improved body condition over pregnant
females that require additional food resources to produce and rear an offspring. However, for
free-ranging large ungulates, empirical evidence supporting [72] or refuting [73–75] this pre-
diction is limited and equivocal. In this investigation, contracepted mares that experienced no
gestation and lactation did not exhibit improved body condition over mares that successfully
reproduced. Individual mares in each experimental group, attained an average BCS of 5.0
(moderate) or better, which has been reported to be the minimally optimal level of stored fat
necessary to achieve maximum reproductive efficiency during pregnancy and lactation [53,
76]. These levels of body condition were reflected in the high proportion of pregnant mares
(0.85–0.92) observed in each treatment group at the management roundups in 2009 and 2013.
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We acknowledge that our sampling intensity and/or sensitivity of our ocular index to body
condition may not have enabled us to detect fine-scale differences between experimental
groups. However, we conducted these evaluations during time periods when differences in
body condition between pregnant and non-pregnant (GonaCon-treated) females should have
been the greatest. Namely, during early spring (March) when fats deposits are depleted over
winter and during April–August when the energetic demands of late gestation and lactation
are increasing.
The body condition of an animal is dependent on a balance between energy intake and
expenditure. When intake is not sufficient to meet energy requirements for various activities
(i.e. maintenance, growth, activity, gestation, lactation, etc.), fat reserves and eventually lean
body tissue will be lost. The fact that pregnant and lactating mares in this study were in similar
body condition to that of contracepted ones suggest that food is unlikely a limiting factor for
free-ranging horses at THRO. This is primarily due to the conservative management of multi-
ple species of ungulates and their food resources [77–79]. The consequence of this approach is
that only under the most extreme climatic conditions, such as prolonged drought, will forage
be limiting to herbivores at THRO, regardless of reproductive status.
The only detectable adverse side effect of vaccination was intramuscular swelling at the vac-
cination site. Mares treated with GonaCon-Equine consistently showed evidence of inflamma-
tory reactions at the injection site. While we never observed lameness associated with this
reaction, several mares revealed draining abscesses within one-year post-vaccination. This is
consistent with results for other wild ungulates treated with the same or similar GonaCon vac-
cines [13, 15, 34]. Given the designed highly inflammatory nature of both the adjuvant, which
contains killed mycobacteria and non-biodegradable oil, as well as, the foreign protein carrier
molecule, these types of reactions are predictable. In fact, they are likely necessary for optimum
vaccine efficacy [80]. It is impossible to assess the total impact of these lesions on animal wel-
fare; however, in this investigation, these did not have a measurable effect on body condition,
locomotion, or social behaviors. Therefore, until additional research suggests otherwise, we
conclude that the presence of injection site lesions following GonCon vaccination do not pose
a serious contraindication associated with the application of this vaccine, and there appear to
be minimal long-term effects on individual animal welfare.
Conclusions
Controlling abundance of wildlife species that are simultaneously protected, abundant, com-
petitive for resources, and in conflict with some stakeholders is a formidable challenge for
resource managers. We demonstrated that the GnRH vaccine, GonaCon-Equine, could be an
effective immunocontraceptive for free-ranging feral horses, particularly when the primary
vaccination is followed by reimmunization four years later. This vaccine was shown to be safe
for pregnant females and neonates and did not result in deleterious behavioral side effects dur-
ing the foaling/breeding season. The only adverse reactions to vaccination were non-debilitat-
ing inflammatory responses at injection sites. One noteworthy implication has emerged
regarding long-term management of free-ranging horse populations using GonaCon-Equine
vaccine: effective management and development of population models will need to incorpo-
rate repeat immunizations of this vaccine to optimize management strategies aimed at stabiliz-
ing the growth rate of feral horse populations. Our research suggests that practical application
of this vaccine in feral horses will require an initial inoculation that may provide only modest
suppression of fertility followed by reimmunization over time that together could result in
greater reduction in population growth rates. Future research will begin to define the most
effective revaccination schedule with GonaCon-Equine for suppressing reproductive rates in
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free-ranging horses, the duration of effectiveness, and the return to fertility following treat-
ment. Moreover, applying GonaCon-Equine to control the growth of feral horse populations
will require that resource managers choose specific tactics for treating animals. Choices must
be made on the number and age to treat and the frequency of treatment needed to maintain
the desired population age structure and genetic diversity. Decisions on the most beneficial
tactics will depend on overarching management goals and long-term objectives for the
population.
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